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Background: Limiting oxidative stress to the ovarian epithelium has been proposed as a first-line defense against
ovarian cancer. Although evidence for an association between individual dietary antioxidant intake and ovarian
cancer risk is conflicting, the combined evidence suggests a modest inverse association. Our study aimed to
evaluate the association between total antioxidant capacity (TAC) and individual antioxidant intakes (vitamin C,
vitamin E, beta-carotene, selenium, lutein, and lycopene) and ovarian cancer risk.
Methods: We conducted a population-based case–control study in New Jersey. Cases were women ages 21 years
and older with newly diagnosed epithelial ovarian cancer who resided in six counties of New Jersey. Controls were
women in the same age range who resided in the same geographic area. A total of 205 ovarian cancer cases and
390 controls were included. Dietary intake was ascertained using the Block food frequency questionnaire (FFQ), and
TAC indices were constructed by linking FFQ-derived estimates to two standardized antioxidant capacity databases,
the USDA Oxygen Radical Absorbance Capacity (ORAC) Database, and the University of Olso’s Antioxidant Food
Database. Multivariate logistic regression models were used to calculate odds ratios and 95 % confidence intervals
while controlling for major ovarian cancer risk factors.
Results: We found a strong inverse association with selenium from food sources (OR: 0.41; 95 % CI: 0.20-0.85, for
the highest vs. lowest tertile of dietary selenium intake). However, there was little evidence of an association with
dietary TAC or the others individual antioxidants. In contrast, compared to non-users, supplement users had
significant increased risk for all micronutrients, but no statistically significant increased risk was observed for
combined intake from foods and supplements of any of these antioxidants.
Conclusions: This study found an inverse association between selenium consumption from food sources and
ovarian cancer risk, while there was little evidence of an association with TAC or any of the other individual
antioxidants. Additional research is needed to confirm these findings.
Keywords: Ovarian neoplasms, Antioxidants, Total antioxidant capacity, Vitamin C, Vitamin E, Beta-carotene,
Selenium, Lutein, Lycopene, DietIntroduction
Ovarian cancer is associated with the highest mortality
among all gynecologic cancers [1]. Ovarian cancer is com-
monly referred to as a “silent killer”, as symptoms are often
non-specific and women are therefore diagnosed in late
stages of disease. Approximately 21,990 women were* Correspondence: elisa.bandera@umdnj.edu
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reproduction in any medium, provided the ordiagnosed in 2011, and 15,460 women died from ovarian
cancer [1].
In ovarian cancer, more than 90 % of cancers originate
from the surface epithelial cells [2]. The etiologic theory of
incessant ovulation was proposed in the 1970’s by Fathalla
[3], which suggests that repeated ovulations are respon-
sible for transformation of the ovarian epithelium. Add-
itional studies have shown that ovarian surface epithelial
cells surrounding follicular rupture are exposed to muta-
gens, including both inflammatory mediators and oxidants,
which are produced during the periovulatory period [4,5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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oxidants are produced in excess. Additionally, processes
which occur during periovulatory remodeling cause ovar-
ian surface epithelial cells to suffer genomic damages lead-
ing to apoptosis, and surrounding cells are exposed to
excessive reactive oxidants. Animal and human experi-
mental studies have confirmed that surface ovarian epithe-
lial cells contain elevated levels of 8-oxoguanine during
ovulation, which is one of the most important mutagenic
lesions in DNA [6,7]. It has therefore been suggested that
limiting oxidative stress to the ovarian epithelium could be
considered a first-line defense against ovarian cancer [6].
Although evidence for an association between individ-
ual dietary antioxidant intake and ovarian cancer risk is
conflicting [8], the combined role of these micronutri-
ents in the prevention of ovarian cancer has not been
elucidated. As both individual contributions from micro-
nutrients and combined additive or synergistic effects
may alter risk, understanding the combined effect of
antioxidant micronutrients on the risk of ovarian cancer
may also help to develop a better understanding of their
role in disease prevention.
We therefore sought to investigate the association be-
tween total antioxidant capacity (TAC) intake and ovar-
ian cancer risk using data from standardized antioxidant
databases in a population-based case–control study con-
ducted in New Jersey [9,10]. As few studies have investi-
gated the role of antioxidant supplement intake and
ovarian cancer risk, and evidence on individual dietary
antioxidants is inconclusive, we also investigated the as-
sociation between individual antioxidant micronutrients
from food and supplements with ovarian cancer risk.
Methods
The NJ Ovarian Cancer Study has been described in de-
tail elsewhere [9,10]. It was designed using identical
study instruments and a shared control group with the
EDGE Study (Estrogen, Diet, Genetics, and Endometrial
Cancer) [11,12], and was conducted in a collaboration
between the Cancer Institute of New Jersey (CINJ), Me-
morial Sloan-Kettering Cancer Center (MSKCC), and
the New Jersey State Cancer Registry (NJSCR), based at
the New Jersey Department of Health and Senior Ser-
vices (NJDHSS).
In brief, cases were women with newly diagnosed histo-
logically confirmed invasive epithelial ovarian cancer iden-
tified between January 2004 and May 2008. Ovarian
cancer cases aged 21 years or older who spoke English or
Spanish and resided in six counties of New Jersey (Bergen,
Essex, Hudson, Middlesex, Morris, or Union) were eligible
to participate. Case ascertainment was conducted by the
NJSCR using rapid case ascertainment, supplemented with
review of NJSCR data to identify cases diagnosed out of
the area. During the study period, 493 women wereidentified. Of those, 61 passed away before they could be
interviewed, for 9 cases their physicians advised that we
should not contact them, and an additional 119 cases were
not able to participate for various reasons (e.g., found to
be ineligible, unable to reach, communication barriers,
comorbidities). Of the remaining women, 233 (47 %) ovar-
ian cancer cases completed the interview.
Controls were women 21 years and older who resided
in the same six counties as the cases (Bergen, Essex,
Hudson, Middlesex, Morris, or Union) and spoke English
or Spanish. Women who had a hysterectomy and/or a
bilateral oophorectomy were not eligible to participate.
To identify controls aged< 65 years, random digit dial-
ing was conducted. Of the 355 eligible women identified,
175 (49 %) completed the interview. To identify women
> 65 years of age, random selection was conducted from
lists purchased from the Centers for Medicare and Me-
dicaid. Of the 316 women who were contacted, 68
(22 %) completed the interview. However, the eligibility
of 40 % was unknown. We conducted area sampling to
identify additional controls older than 65 years, starting
in 2003. Thirty consecutive households in randomly
chosen neighborhoods were contacted by mail and by
home visits. To better match the age distribution of the
cases women aged 55 years and older were later
included. Overall, 467 (40 %) controls completed the
interview.
Informed consent was provided by all women partici-
pating in the studies, and IRB approval was obtained
from the CINJ, MSKCC, and the NJDHSS.
Data collection
A questionnaire was administered to participants to collect
data on potential and established ovarian cancer risk factors.
Information on demographic characteristics, residential his-
tory, pregnancy history, occupation, oral contraceptive use
and other birth control methods, menstrual history and
menopausal status, personal and family history of cancer
and other illnesses, height and weight, physical activity, and
exposure to other potential risk factors was included.
To assess dietary intake, participants were asked to
complete the Block Food Frequency Questionnaire (FFQ),
version 98.2 (NutritionQuest, Berkeley, CA). Patients
reported their usual dietary intake in the six months prior
to their date of entry into the study for controls and their
diagnosis date for cases. A total of 205 ovarian cancer
cases and 398 controls completed the FFQ. Eight controls
were further excluded as they had both ovaries removed
and were therefore ineligible, leaving 390 controls available
for analysis.
NutritionQuest provided nutrient calculations for indi-
vidual antioxidants using the USDA Nutrient Database for
Standard Reference. We derived TAC indices by linking
FFQ-derived food consumption to two standardized
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Absorbance Capacity (ORAC) Database (http://www.ars.
usda.gov/sp2userfiles/place/12354500/data/orac/orac07.
pdf), and the University of Olso’s Antioxidant Food Data-
base [13].
Total daily intake of food items known to be high in
antioxidant content from the FFQ, including over 50
food items, such as fruits, vegetables, juices, grains, teas,
chocolate and wine was computed first. Daily consump-
tion was derived based on frequency and portion size,
and food values were converted from their unit listed in
the FFQ to grams per day, using values from the USDA
Nutrient Database for Standard References (www.nal.
usda.gov).
The ORAC database, developed by the USDA Agricul-
tural Research Service, was utilized to develop individual
indices for TAC: total antioxidant capacity (T-ORAC),
hydrophilic antioxidant capacity (H-ORAC), lipophilic
antioxidant capacity (L-ORAC), and total phenolics (TP).
Additionally, antioxidant values were derived using an-
other database, the Antioxidant Food (FRAP) database,
which is based on the electron transfer FRAP assay to
extract antioxidant values. Both databases were used to
assess the comparability of results using the two assays.
Antioxidant values were attributed to each food item
based on the data in the antioxidant databases. The total
umol of Trolox Equivalents per 100 grams per day for
each food item and total mg gallic acid equivalents per
100 grams per day for each food item were calculated,
and the total of all items were summed to develop each
of the indices. Separate antioxidant indices were devel-
oped for total H-ORAC, L-ORAC, T-ORAC, and TP,
from the ORAC database, and a TAC index was devel-
oped from the Antioxidant Food (FRAP) Database. As
the ORAC database does not include values for antioxi-
dant supplements, to compare the results of the TAC
index from the ORAC database to that of the FRAP
database, a TAC index without supplements based on
the FRAP index was also developed.
Data analysis
The relationship between ovarian cancer and the TAC in-
dices and individual antioxidants (vitamin C, vitamin E,
beta-carotene, lycopene, lutein, and selenium, from food
sources, supplements, and food and supplements com-
bined) was assessed by evaluating the indices as categorical
variables. Tertiles of each TAC index were created based
on the distribution of each index among controls. Age-
adjusted ANCOVA and cross-tabulations were conducted
to assess any association between the TAC indices and
case–control status. Multiple unconditional logistic regres-
sion models were developed to estimate odds ratios and
95 % confidence intervals while controlling for potential
confounders. Potential covariates included age, body massindex (BMI), education (high school or less, college, gradu-
ate school), race, age at menarche (continuous), meno-
pausal status, parity (0–1, 2, >3), oral contraceptive use
(ever, never), hormone replacement therapy (HRT) use
(never, used unopposed estrogen only, used combined
therapy), tubal ligation, total energy intake (continuous),
smoking status (never, current, former), alcohol consump-
tion (continuous), and physical activity (continuous total
metabolic equivalents). Tests for trend were derived by
assigning a median value to each tertile of the antioxidant
variables. All analyses were conducted using SAS software
version 9.2.
Results
Demographic and patient characteristics are presented in
Table 1. The majority of participants were white. As
expected, odds ratios were below one for oral contracep-
tive use, higher parity, and a prior tubal ligation, and
above one for having a first degree relative with ovarian
cancer.
Tables 2 and 3 show the age-adjusted mean intake for
each TAC index and individual antioxidant micronutri-
ents among cases and controls. Cases tended to have a
slightly lower intake of total antioxidants. However, no
significant differences were observed between cases and
controls for any of the TAC indices or individual
micronutrients.
After adjusting for major risk factors, there was little
evidence of an association with any of the TAC indices,
as shown in Table 4. No association was observed for
consumption of vitamin C, vitamin E, or beta-carotene
from food sources, as shown in Table 5. However, intake
of selenium from food sources was associated with a
strong, significant inverse association with ovarian can-
cer risk (OR: 0.41; 95 % CI: 0.20-0.85 for the highest ter-
tile compared to the lowest). In contrast, compared to
non-users, ovarian cancer risk was elevated for supple-
ment users of all individual antioxidants examined, with
ORs (95 % CI) of 1.63 (1.01-2.62) for vitamin C, 1.63
(1.02-2.63) for vitamin E, 1.69 (1.08-2.66) for beta-caro-
tene, and 1.64 (1.05-2.56) for selenium supplement users.
No association was observed when the amount of anti-
oxidant supplement intake was combined with dietary
intake. There was a suggestion of increased risk for diet-
ary lycopene (OR: 1.54; 95%CI: 0.90-2.62) and lutein
(OR: 1.48; 95%CI: 0.82-2.68), but it was not statistically
significant.
Discussion
In this study we found little evidence that the dietary
TAC had an impact on ovarian cancer risk, based on
antioxidant content values from the USDA ORAC data-
base and the FRAP-based Antioxidant Food Database. In
line with these findings, most individual micronutrients
Table 1 Selected characteristics of women participating in The NJ Ovarian Cancer Study
Cases (n=205) n (%) Controls (n=391) n (%) OR (95 % CI)*
Education
High school or less 61 (29.8) 133 (34.0) 1.00 (Ref)
College 93 (45.4) 159 (40.7) 0.90 (0.59-1.38)
Graduate school 51 (24.9) 99 (25.3) 0.76 (0.47-1.24)
Race/ethnicity
White 179 (87.3) 344 (88.4) 1.00 (Ref)
Black 9 (4.4) 17 (4.4) 1.02 (0.42-2.44)
Other 8 (3.9) 17 (4.4) 0.82 (0.33-1.99)
Hispanic (any race) 9 (4.4) 11 (2.8) 1.13 (0.44-2.92)
BMI
Underweight (<18.5) 1 (0.5) 1 (0.3) 1.02 (0.06-17.31)
Normal (18.5-25) 90 (43.9) 180 (46.4) 1.00 (Ref)
Overweight (25–29.9) 54 (26.3) 122 (31.4) 1.07 (0.69-1.65)
Obese (30–34.9) 36 (17.6) 59 (15.2) 1.39 (0.83-2.32)
Very obese (>35) 24 (11.7) 26 (6.7) 1.54 (0.81-2.89)
Parity
0 – 1 97 (47.3) 92 (23.5) 1.00 (Ref)
2 60 (29.3) 137 (35.0) 0.45 (0.29-0.69)
>3 48 (23.4) 162 (41.4) 0.42 (0.26-0.66)
Smoking status
Never 108 (52.7) 204 (52.2) 1.00 (Ref)
Past 78 (38.1) 149 (38.1) 1.12 (0.76-1.64)
Current 19 (9.3) 38 (9.7) 0.87 (0.46-1.62)
Oral contraceptive use
Never 85 (41.5) 193 (49.4) 1.00 (Ref)
Ever 120 (58.5) 198 (50.6) 0.88 (0.61-1.28)
Use of HRT
Never 159 (77.6) 285 (72.9) 1.00 (Ref)
Unopposed E only 22 (10.7) 34 (8.7) 1.56 (0.86-2.84)
Any combined HRT 24 (11.7) 72 (18.4) 0.63 (0.38-1.06)
Age at menarche
>13 41 (20.1) 99 (25.4) 0.81 (0.51-1.27)
12-13 117 (57.4) 200 (51.3) 1.00 (Ref)
<11 46 (22.6) 91 (23.3) 0.75 (0.48-1.17)
Menopause status
Premenopausal 71 (34.6) 49 (12.5) 1.51 (0.85-2.69)
Postmenopausal
Age at menopause
<40 5 (2.4) 14 (3.6) 0.77 (0.26-2.31)
41-54 86 (42.0) 239 (61.3) 1.00 (Ref)
>55 12 (5.9) 37 (9.5) 0.99 (0.48-2.01)
Unknown 31 (15.1) 52 (13.3) 1.52 (0.91-2.56)
Tubal Ligation
No 175 (85.4) 315 (80.6) 1.00 (Ref)
Yes 30 (14.6) 76 (19.4) 0.59 (0.36-0.94)
First relative with ovarian cancer
No 195 (95.1) 377 (96.4) 1.00 (Ref)
Yes 10 (4.9) 14 (3.6) 1.32 (0.55-3.17)
*Adjusted for age.
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Table 2 Age-adjusted mean total antioxidant capacity intake based on antioxidant indices in cases and controls
Mean (SE)
Cases Controls p value
H-ORAC, umolTE/100 g 13,000 (504) 13,488 (361) 0.44
L-ORAC, umolTE/100 g 394 (20) 437 (14) 0.08
T-ORAC, umolTE/100 g 13,275 (514) 13,809 (368) 0.41
TP, mgGAE/100 g 1776 (71) 1821 (50) 0.61
FRAP, umolTE/100 g 5,361 (214) 5,446 (153) 0.75
FRAP, with supplements, umolTE/100 g 13,051 (807) 12,716 (577) 0.74
H-ORAC: Hydrophilic oxygen radical absorbance capacity; L-ORAC: Lipophilic oxygen radical absorbance capacity; T-ORAC: Total oxygen radical absorbance
capacity; TP: Total phenolics; TE: Trolox equivalents; GAE: Gallic acid equivalents; SE: Standard error.
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ian cancer, with the exception of selenium. We found a
statistically significant 60 % decreased risk of ovarian
cancer for women in the highest tertile of selenium in-
take from food sources compared to the lowest. In con-
trast, we observed significant increased risk for users of
all types of antioxidant supplements examined, com-
pared to non-users. However, no increased risks were
observed for the total amount of antioxidant intake when
supplement amounts were combined with dietary intake.
Similar to our results, most studies investigating diet-
ary vitamin C and ovarian cancer risk report no associ-
ation [14-23]. However, some studies have found
significant decreased risks [24-28]. The only two cohort
studies evaluating vitamin C reported no association,Table 3 Age-adjusted mean antioxidant micronutrient intake
Cases
Vitamin C, mg/1,000 kcal
Food 117.5 (5.0)
Supplements 309.4 (31.9)
Total intake 426.9 (32.8)
Vitamin E, aTE/1,000 kcal
Food 10.0 (0.4)
Supplements 83.3 (10.8)




Total intake 6039.5 (477.5)
Selenium, mcg/1,000 kcal
Food sources 74.9 (2.6)
Supplements 23.2 (3.3)
Total intake 98.1 (4.5)
Lutein (food), mcg/1,000 kcal 1750.3 (108.9)
Lycopene (food), mcg/1,000 kcal 5454.1 (394.3)
SE: Standard error; aTE: alpha tocopherol equivalents.including an analysis of the Nurse’s Health Study, which
identified 301 ovarian cancer cases during a follow-up of
16 years [23]. Additionally, a meta-analysis of case-con-
trols studies found no association, reporting a pooled OR
of 0.98 (95 % CI: 0.95-1.01) for additional daily intake of
30 mg vitamin C [8]. Only one other study has investi-
gated supplement use, and in contrast to our results
found a significantly decreased risk of almost 50 %, and
also reported a decreased risk for supplements combined
with dietary intake [18].
We also found no association with vitamin E intake.
Similarly, of all previously conducted studies evaluating
vitamin E and ovarian cancer risk [14-18,21-24,26,29-
31], most found no association. Only a few case–control
studies reported decreased risks [17,24,26,31]. Infrom foods and supplements
Mean (SE)















Table 4 Total antioxidant capacity intake based on antioxidant indices and ovarian cancer risk
Cases (n) Controls (n) OR1 95 % CI OR2 95 % CI
ORAC Database
H-ORAC (umolTE/100 g)
1 (<9,505) 75 128 1.00 1.00
2 (9,505-15,552) 65 132 0.93 0.58-1.49 0.93 0.55-1.56
3 (>15,553) 65 127 1.01 0.64-1.77 1.19 0.69-2.01
p for trend 0.68 0.65
L-ORAC (umolTE/100 g)
1 (<275.9) 74 127 1.00 1.00
2 (275.9-470.4) 73 132 0.87 0.54-1.41 0.83 0.48-1.41
3 (>470.5) 58 128 0.84 0.49-1.44 0.91 0.50-1.64
p for trend 0.62 0.48
T-ORAC (umolTE/100 g)
1 (<9,760) 74 127 1.00 1.00
2 (9,760-16,040) 70 133 1.01 0.63-1.61 1.03 0.61-1.72
3 (>16,041) 61 127 0.98 0.58-1.64 1.09 0.62-1.94
p for trend 0.95 0.96
Total phenolics (mgGAE/100 g)
1 (<1,315) 85 131 1.00 1.00
2 (1,315-2,180) 64 134 0.88 0.55-1.40 1.13 0.68-1.88
3 (>2,181) 56 130 0.84 0.50-1.41 0.88 0.49-1.59
p for trend 0.66 0.54
FRAP (umolTE/100 g)
1 (<3,951) 52 127 1.00 1.00
2 (3,951-6,482) 82 133 0.81 0.51-1.31 0.92 0.55-1.53
3 (>6,483) 71 127 1.00 0.61-1.65 1.07 0.62-1.86
p for trend 0.36 0.66
FRAP with supplements (umolTE/100 g)
1 (<6,261) 52 127 1.00 1.00
2 (6,261-14,110) 81 133 1.20 0.79-2.06 1.18 0.65-2.14
3 (>14,111) 72 127 1.15 0.63-2.08 1.27 0.66-2.43
p for trend 0.52 0.65
ORAC: Oxygen radical absorbance capacity; H-ORAC: Hydrophilic oxygen radical absorbance capacity; L-ORAC: Lipophilic oxygen radical absorbance capacity; T-
ORAC: Total oxygen radical absorbance capacity; TE: Trolox equivalents;GAE: gallic acid equivalents; OR: Odds Ratio; CI: Confidence interval.
OR1: adjusted for age (continuous), education, race, age at menarche (continuous), menopausal status and age at menopause for postmenopausal women, parity,
OC use, HRT use, BMI (continuous), tubal ligation, antioxidant supplement intake, and total calories; OR2: further adjusted for physical activity (METs), and smoking
status.
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ing supplement use reported strong inverse associations
[18,30].
Consistent with our findings, several cohort studies
[14,15,22,23] and some case–control studies [16,18,32]
found no association with beta-carotene from food
sources. Also, a meta-analysis of case–control studies
reported no association (pooled OR: 0.98; 95 % CI: 0.96-
0.99) for additional daily intake of 500mcg beta-carotene
[8]. However, an inverse association with beta-carotene
has been reported in other studies [17,26,27,29,31], and
non-significant decreased risks have also been reported
[21,33]. To our knowledge, our study is the first toinvestigate beta-carotene supplement use and ovarian
cancer risk.
In support of our findings, a nested case–control study
investigating the serum selenium status of ovarian cancer
patients compared to healthy controls found that in-
creasing serum selenium was associated with a decreased
risk of ovarian cancer (OR: 0.23; 95%CI: 0.1-0.9 for high-
est tertile compared to lowest; p for trend = 0.02) [34].
Das and Ma (1986) reported similar findings, with a re-
verse correlation between serum selenium concentration
and ovarian cancer incidence[35]. Additionally, Sieja
(1998) found ovarian cancer patients had significantly
lower serum selenium concentrations compared to
Table 5 Antioxidant micronutrients from food and supplements and ovarian cancer risk
Cases (n) Controls(n) OR1 95 % CI OR2 95 % CI
Vitamin C
Food (mg)
1 (<82.3) 75 127 1.00 1.00
2 (82.3-141.7) 72 132 0.93 0.58-1.48 1.08 0.65-1.79
3 (>141.8) 58 128 0.99 0.59-1.67 1.29 0.72-2.29
p for trend 0.75 0.89
Supplements
No 56 111 1.00 1.00
Yes 149 276 1.34 0.87-2.06 1.63 1.01-2.62
Combined food and supplements (mg)
1 (<147.5) 74 128 1.00 1.00
2 (147.5-458.6) 72 132 1.09 0.69-1.74 1.38 0.83-2.31
3 (>458.7) 59 127 1.06 0.66-1.71 1.42 0.84-2.40
p for trend 0.72 0.28
Vitamin E
Food (aTE)
1 (<7.4) 69 128 1.00 1.00
2 (7.4-11.5) 64 132 0.96 0.56-1.65 0.94 0.53-1.67
3 (>11.6) 72 127 1.04 0.55-1.98 0.89 0.45-1.77
p for trend 0.84 0.89
Supplements
No 58 114 1.00 1.00
Yes 147 273 1.35 0.88-2.07 1.63 1.02-2.63
Combined food and supplements (aTE)
1 (<21.7) 69 128 1.00 1.00
2 (21.7-114.8) 88 131 1.53 0.98-2.41 1.81 1.10-1.04
3 (>114.9) 48 128 0.87 0.52-1.42 1.03 0.59-1.78
p for trend 0.29 0.10
Beta-carotene
Food (mcg)
1 (<2,070) 67 128 1.00 1.00
2 (2,070-3,675) 66 132 1.14 0.70-1.86 1.05 0.61-1.78
3 (>3,676) 72 127 1.35 0.81-2.25 1.45 0.83-2.52
p for trend 0.61 0.91
Supplements
No 67 138 1.00 1.00
Yes 138 249 1.40 0.93-2.11 1.69 1.08-2.66
Combined food and supplements (mcg)
1 (<3,040) 79 128 1.00 1.00
2 (3,040-5,075) 57 132 0.82 0.51-1.33 0.87 0.52-1.47
3 (>5,076) 69 127 1.09 0.67-1.79 1.38 0.80-2.35
p for trend 0.33 0.41
Selenium
Food (mcg)
1 (<59.5) 84 128 1.00 1.00
2 (59.5-87.7) 58 132 0.48 0.28-0.81 0.55 0.31-0.98
3 (>87.8) 63 127 0.40 0.21-0.78 0.41 0.20-0.85
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Table 5 Antioxidant micronutrients from food and supplements and ovarian cancer risk (Continued)
p for trend 0.01 0.10
Supplements
No 69 148 1.00 1.00
Yes 136 239 1.44 0.95-2.15 1.64 1.05-2.56
Combined food and supplements (mcg)
1 (<72.4) 79 128 1.00 1.00
2 (72.4-103.6) 58 132 0.69 0.42-1.16 0.73 0.42-1.27
3 (>103.7) 68 127 0.73 0.40-1.30 0.75 0.39-1.43
p for trend 0.20 0.30
Lutein
Food (mcg)
1 (<1,019) 65 128 1.00 1.00
2 (1,019-1,882) 65 131 1.21 0.74-1.97 1.28 0.75-2.19
3 (>1,882) 75 128 1.46 0.89-2.39 1.54 0.90-2.62
p for trend 0.63 0.51
Lycopene
Food (mcg)
1 (<2,504) 51 127 1.00 1.00
2 (2,504-5,464) 83 133 1.68 1.01-2.79 1.43 0.83-2.47
3 (>5,465) 71 127 1.58 0.91-2.74 1.48 0.82-2.68
p for trend 0.05 0.26
OR1: adjusted for age (continuous), education, race, age at menarche (continuous), menopausal status and age at menopause for postmenopausal women, parity,
OC use, HRT use, BMI (continuous), tubal ligation, and total calories; OR2: further adjusted for physical activity (METs) and smoking status.
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http://www.biomedcentral.com/1471-2407/12/211controls (p< 0.05), approaching critical levels, particu-
larly during chemotherapy treatment[36]. However, other
studies investigating selenium intake from dietary and
supplement sources [14,18,21], including an analysis of
the Women’s Health Initiative [14], found no association
with ovarian cancer risk. Tung et al. [21] assessed selen-
ium intake among a multiethnic group of patients from
Hawaii and Los Angeles and Fleischauer et al. [18] had a
smaller number of cases (n = 169), and used both com-
munity and hospital-based controls. Differences in the
study populations may partially explain the conflicting
results.
Numerous studies have indicated that selenium may
have anticancer properties. Human studies have shown a
decrease in the incidence of prostate, lung, and colorectal
cancers [37,38]. Additionally, animal studies have shown
that, at high doses, selenium compounds reduce tumor
yields, inhibit cell growth, and stimulate programmed cell
death in cultures. In ovarian cancer cells, it has been
demonstrated that selenium compounds inhibit the syn-
thesis of nucleic acids (Rzaeva, 1985). Selenoprotein defi-
ciency has also been found to be present in certain types
of cancer. The proposed mechanism by which selenium
may have a protective effect on cancer is mainly through
its antioxidant properties. Selenium provides antioxidant
protection against the effect of reactive oxygen species oncancer initiation and promotion [39]. Geographic variation
in selenium concentrations exists, however no study has
investigated whether ovarian cancer risk differs in areas
with varying selenium concentrations.
Our conflicting findings of a protective effect asso-
ciated with dietary selenium intake versus an increased
risk associated with supplement intake are unclear. Of
note, the increased risk observed with selenium supple-
ments only reached statistical significance after further
adjustment for physical activity and smoking status. It is
possible that related unmeasured confounders may be
influencing the association. Studies of supplement intake
and relation with cancer risk have been conflicting. A re-
cent systematic review concludes that evidence does not
support selenium supplementation in the prevention of
cancer [40]. Other reports have suggested that certain
supplements may increase the risk of cancer, as has been
recently observed with vitamin E supplementation and
prostate cancer risk [41].
Only one other study has developed a total antioxidant
score in ovarian cancer patients, using data from the
Teacher’s Health Study in California [15]. However, this
study only included antioxidant values from fruits and
vegetables, identified from variable literature sources,
and did not assess supplement use. Similar to our results,
no association was observed.
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control studies, such as recall bias and selection bias.
Particularly with our finding of increased risk with sup-
plements, it is possible that cases may have reported use
differently than controls. We also had a low participation
rate. Potential non-participation bias was assessed by
comparing characteristics of women who participated in
this study to cases who did not in the New Jersey State
Cancer Registry during the study time period. Cases that
consented tended to be younger; however the racial/eth-
nic distribution and distributions by histology, stage and
grade were similar. We did not have information on
women who did not end up participating as controls.
However, the distribution of risk factors in this study is
similar to that reported in other studies, which gives us
reassurance in the validity of our data.
In conclusion, this study found a strong inverse associ-
ation of selenium from food sources and ovarian cancer
risk, while selenium supplement intake was associated
with increased risk. However, we did not find any signifi-
cant association between TAC intake and ovarian cancer
risk. Supplement use in this study was found to be asso-
ciated with increased ovarian cancer risk for all supple-
ments studied. However, combined amounts of
antioxidants from diet and supplement sources were not
associated with increased risks. As several reports have
recently raised concerns about the safety of vitamin sup-
plements in recent years, including the 2007 WCRF/
AICR Report which warned cancer patients and survi-
vors against taking certain supplements [8], these find-
ings warrant further investigation to better understand
the role of selenium from foods and supplements on
ovarian cancer risk.
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